Primary Pulmonary NUT Carcinoma: A Case Illustration of Therapeutic Challenges and Review of Emerging Targeted Therapies

Our plain-English summary of Primary Pulmonary NUT Carcinoma: A Case Illustration of Therapeutic Challenges and Review of Emerging Targeted Therapies, by J.Y. Bae, X.Y. Gao, J.K. Dermawan, et al (Case Reports in Oncological Medicine, 2026).

The study

• Authors: J.Y. Bae, X.Y. Gao, J.K. Dermawan, J.A. Hellyer
• Journal: Case Reports in Oncological Medicine
• Published: 2026;2026:4908133
• Cited by: 1 article, as counted by NIH iCite
• Read it: PubMed · Publisher · Free full text

Abstract

Background: Pulmonary NUT carcinoma is a rare but highly aggressive malignancy with poor prognosis. It typically affects younger patients with no smoking history. Given its rapid progression, it is crucial to consider it as a differential diagnosis in a poorly differentiated thoracic mass to ensure timely diagnosis and management.

Case Presentation: We report a case of primary pulmonary NUT carcinoma diagnosed in a 59-year-old male with a never-smoking history during routine screening for possible occupational asbestos exposure. The preliminary diagnosis of metastatic keratinizing squamous cell carcinoma was later reclassified as NUT carcinoma by immunohistochemistry. Next generation sequencing of ctDNA showed CDKN2A mutation. The therapeutic course was complicated by several hypersensitivity reactions to first line treatments. Due to rapidly deteriorating clinical status, the patient was no longer eligible for a BET inhibitor clinical trial and died approximately 5 months after diagnosis.

Conclusion: Due to its rarity and poor therapeutic response, there is currently no established standard of treatment for pulmonary NUT carcinoma. Timely and accurate diagnosis remains challenging due to its nonspecific presentation and rarity, resulting in low clinical suspicion, especially in patients outside the typical demographic. Common first-line treatments include platinum-based regimens in combination with etoposide or paclitaxel. Several clinical trials of BET and histone deacetylase inhibitors are active, and clinicians are encouraged to enroll patients to maximize survival outcomes.

Copyright © 2026 Jessica Y. Bae et al. Case Reports in Oncological Medicine published by John Wiley & Sons Ltd.

In plain English

This article was a case report about one patient with primary pulmonary NUT carcinoma, a rare cancer that in this patient began in the lung. It also included a table summarizing other researchers' studies of treatments under investigation. The patient was a 59-year-old man who had never smoked and who had occupational asbestos exposure, for which he had yearly chest x-rays. Surveillance imaging found a new mass in the left lower lobe of his lung; imaging the year before had been normal. A needle sample first suggested metastatic keratinizing squamous cell carcinoma. A later rib biopsy with special stains confirmed metastatic NUT carcinoma of the lung. Treatment was complicated by a severe reaction to paclitaxel and then anaphylaxis to etoposide. The cancer kept growing during chemotherapy, and his condition worsened too quickly for him to join a clinical trial. He died about 5 months after diagnosis. The authors wrote that no definitive risk factors for this cancer have been established. They noted that the amount and duration of his asbestos exposure were unknown, and that whether it contributed or was incidental cannot be determined.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: Case report of a single patient, with a table summarizing other published studies of treatments under investigation for pulmonary NUT carcinoma
• Who was studied: One 59-year-old male patient with no history of smoking or pre-existing lung disease, referred for a new left lower lobe lung mass found on surveillance imaging
• Exposure: Occupational asbestos exposure, for which the patient had yearly chest x-ray screening. Fiber type, job, cumulative quantity and duration were not reported and were stated to be unknown.
• Main results:
  • Imaging from the year before the diagnosis was normal, with no masses or lesions.
  • PET/CT showed a 9.1 cm left lower lobe mass. A chest CT 6 weeks later showed it had grown to 12.1 cm.
  • Fine needle aspiration gave a preliminary diagnosis of metastatic keratinizing squamous cell carcinoma. Immunohistochemistry stains on a rib biopsy then confirmed metastatic NUT carcinoma of the lung, positive for p40 and NUT.
  • Blood-based circulating tumor DNA sequencing showed a CDKN2A mutation.
  • The patient had a severe hypersensitivity reaction to paclitaxel in the first treatment cycle. He then had anaphylaxis to etoposide.
  • After four cycles of carboplatin with gemcitabine, the disease responded poorly, with rapid growth of the primary tumor and new lesions. The last CT showed the left lung mass at 13.8 cm.
  • Because his condition was deteriorating rapidly, the patient was no longer a candidate for a BET inhibitor clinical trial. He died approximately 5 months after initial diagnosis.
• The authors' conclusion: The authors concluded that NUT carcinoma is hard to diagnose in time because its symptoms are nonspecific, especially in patients outside the typical age group. They wrote that this patient's complex chemotherapy course and rapid progression show the need for continued clinical trials to establish effective therapies.
• Limitations the authors state:
  • The patient's cumulative quantity and duration of asbestos exposure were unknown. Whether the exposure contributed to the diagnosis or was incidental cannot be determined.
  • Because few cases have been reported, no definitive risk factors for primary pulmonary NUT carcinoma have been established.
  • The zygosity of the CDKN2A mutation was unknown, so the authors' interpretation of its role was speculative.

Topics

Medical terms in this study, explained in our Lexicon: Carcinoma, Prognosis, Differential Diagnosis, Asbestos Exposure, Squamous Cell Carcinoma, Immunohistochemistry, ctDNA, CDKN2A.

Related studies

• Comments and Illustrations of the European Federation of Societies for Ultrasound in Medicine (EFSUMB) Guidelines: Rare Malignant Pulmonal and Pleural Tumors: Primary Pulmonary Sarcoma and Mesothelioma, Imaging Features on Transthoracic Ultrasound — K. Möller, F. Dietz, et al. (2024)
• Emerging translational therapies for mesothelioma — H.I. Pass, B.W. Robinson, et al. (1999)
• Emerging therapies in malignant pleural mesothelioma — M. Cinausero, K. Rihawi, et al. (2019)
• Emerging biological therapies for the treatment of malignant pleural mesothelioma — A.P. Davis, S.C. Kao, et al. (2021)
• Editorial: Emerging Therapies for Malignant Mesothelioma — N. van Zandwijk, G. Reid, et al. (2020)
• Expression of metalloproteinases and their inhibitors in primary pulmonary carcinomas — S.J. Urbanski, D.R. Edwards, et al. (1992)

Browse more research in Case Reports in Oncological Medicine, or return to medical research.